Comparing Parkinson's Treatments: Medication Adjustment, Infusion, DBS, and Focused Ultrasound

When medication no longer provides a predictable day, patients may hear recommendations to add a drug, change formulation, use an infusion system, or consider a procedure. These options do not form a simple ladder from ordinary to advanced. First identify the problem: off time, troublesome dyskinesia, tremor, walking, swallowing, or cognition. Each approach has particular targets, selection requirements, and continuing burdens. Without a shared goal, even an extensive list of response rates will not identify the best choice for an individual.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Replace “Does it work?” with an outcome that can be checked: more time moving comfortably, less troublesome involuntary movement, independent eating, or fewer nighttime assistance needs. Distinguish function that remains impaired despite a good medication response elsewhere from disability caused by benefit wearing off. More consistent dopaminergic delivery may not resolve a problem that does not respond to that treatment in the first place.
MRI-guided focused ultrasound concentrates energy at a selected target to produce thermal ablation. It is not an ordinary diagnostic scan or a method of repairing the whole brain. A 2023 sham-controlled study of internal globus pallidus ablation showed improvement in motor function or dyskinesia in some eligible participants, alongside adverse effects affecting functions such as speech and walking. The target, unilateral or bilateral pathway, and principal symptom are essential parts of the comparison. Randomized pallidal focused-ultrasound trial
Bring the two or three symptoms most worth improving, treatments already tried, adverse effects that would be unacceptable, and the support the household can realistically provide. Ask the team to explain its preferred pathway, reasonable alternatives, and what happens if benefit is insufficient. When specialists differ, the disagreement may concern the target or the risk assessment. Request the reasoning rather than being left to vote between procedure names.

Quick answer

Full guide

Compare options against the same clinical question

Replace “Does it work?” with an outcome that can be checked: more time moving comfortably, less troublesome involuntary movement, independent eating, or fewer nighttime assistance needs. Distinguish function that remains impaired despite a good medication response elsewhere from disability caused by benefit wearing off. More consistent dopaminergic delivery may not resolve a problem that does not respond to that treatment in the first place.

The MDS 2025 evidence update assessed several treatments for motor fluctuations, but it is not a universal ranking of first choices. Study populations, comparators, and follow-up periods differed. An efficacy rating does not establish superiority over every other option for every patient. Use the evidence in relation to the individual's clinical situation and most important outcome. MDS motor-fluctuation evidence update

Further medication optimization offers flexibility

Additional adjustment may be worthwhile if wearing off, delayed benefit, meal effects, and dosing schedules have not been systematically reviewed. Changes can involve dose distribution, release formulation, or an additional drug class. This avoids an immediate brain procedure and permits later modification, but can produce a more complicated schedule or adverse effects such as sleepiness, dizziness, and hallucinations.

“Best medication has already been tried” should be supported by a record of the actual regimens, their duration, reasons for stopping, and whether the patient could follow them. One unsuccessful medicine does not establish failure of all pharmacological options. Equally, repeatedly prescribing an intolerable combination should not postpone assessment of a reasonable alternative. NICE recommends specialist involvement when fluctuations or dyskinesia require changes. NICE motor-treatment recommendations

Continuous infusion trades some dosing variability for system care

Continuous delivery aims to make medication effect steadier in selected patients with substantial fluctuations. Different infusion drugs and routes should not be treated as one generic “pump therapy.” In its randomized trial population, subcutaneous foslevodopa–foscarbidopa increased on time without troublesome dyskinesia and reduced off time, while treatment-related problems and discontinuations also occurred. Randomized subcutaneous-infusion trial

The practical comparison includes skin care, connections, backup medication, consumables, and what happens if the system fails, rather than only the number of tablets avoided. Hand function, vision, understanding, and caregiver support influence whether the system can be managed reliably. Initial training does not eliminate future support needs. If the same medication or supplies cannot be obtained after returning home, reconsider that issue before treatment begins.

Continuous subcutaneous apomorphine is another evidence-supported pathway. TOLEDO found reduced off time in patients whose existing treatment did not adequately control fluctuations. Its numerical results cannot be directly ranked against those of a different infusion medicine because populations and comparators differed. Selection should consider hypotension, sleepiness, psychiatric and behavioral risks, skin tolerance, and other medication. TOLEDO randomized trial

DBS offers adjustable stimulation with an implanted system

Deep brain stimulation uses implanted electrodes and a pulse generator to influence selected brain circuits. It can be assessed for appropriate patients, particularly where medication still helps but fluctuations or dyskinesia remain difficult. Parameters can be changed as symptoms and stimulation-related adverse effects evolve. Implantation nevertheless carries risks, including bleeding and infection, and later care can involve hardware or battery problems.

European guidance supports subthalamic nucleus or internal globus pallidus stimulation in defined patient groups. Target selection is not determined solely by a device brand: symptom goals, cognition, mental health, and medication-reduction priorities can matter. DBS cannot reliably correct every medication-unresponsive balance, speech, or cognitive problem. It should not be described as a curative operation that stops Parkinson's progression. EAN–MDS invasive-therapy guideline

Understand the additional question posed by adaptive DBS

Adaptive stimulation uses relevant recorded signals to alter stimulation delivery in a particular system. The FDA's 2025 approval retained defined eligibility conditions. It did not mean that every existing stimulator could be upgraded or that a clinician would no longer be needed for programming. For the patient, the useful question is whether this feature can add a meaningful benefit for the present symptom pattern.

The receiving Chinese team should explain local registration and available functions, the adjustment process, and support in the patient's home country. When comparing conventional and adaptive stimulation, ask what patients contributed to the evidence and which expected improvements are realistic for this individual. A technology label alone is insufficient justification for added cost or complexity. FDA adaptive-stimulation approval

Focused ultrasound creates a lesion rather than an adjustable setting

MRI-guided focused ultrasound concentrates energy at a selected target to produce thermal ablation. It is not an ordinary diagnostic scan or a method of repairing the whole brain. A 2023 sham-controlled study of internal globus pallidus ablation showed improvement in motor function or dyskinesia in some eligible participants, alongside adverse effects affecting functions such as speech and walking. The target, unilateral or bilateral pathway, and principal symptom are essential parts of the comparison. Randomized pallidal focused-ultrasound trial

The absence of an implanted electrode removes some hardware responsibilities, but the lesion cannot be cancelled by changing a setting. Persistent functional difficulties after ablation require a different response from reprogramming stimulation. Ask about suitability for the MRI environment, skull and target requirements, and why the selected target matches the symptoms. An incisionless procedure still requires a discussion of neurological harm.

Treat a second-side lesion as a separate decision

In July 2025, the FDA expanded indications for a specified Exablate system to include staged pallidothalamic tract procedures in eligible patients, with at least six months between procedures. This is not a general authorization for every focused-ultrasound technique to be performed on both sides, and it does not establish Chinese registration. FDA approval letter

A prospective single-arm study published in 2026 reported that 10 of 40 participants receiving bilateral treatment had persistent moderate or severe adverse events 12 months after the second procedure, mainly involving speech, gait, and balance. The investigators judged the additional motor gains after the second side to be small while persistent risks increased. This evidence belongs in counseling; a video of improved shaking is not a sufficient account. The study proportion also should not be presented as an exact personal risk for every prospective patient. 2026 staged bilateral study

Keep rehabilitation and nonmotor care in the comparison

Whatever drug or procedure is selected, walking strategies, functional practice, and the caregiving environment may still need attention. If the main goal is fewer falls, easier meals, or clearer communication, establish whether the corresponding assessments have been completed. The most relevant intervention may involve another professional. A complex device cannot be assumed to replace every other component of care.

Physical-therapy guidance supports selecting exercises according to symptoms and ability. The practical comparison should include whether training can continue at home. A regimen that reduces off time but leaves the patient afraid to move because of adverse effects needs reassessment of its overall value. Recording drug or device response separately from the ability to perform tasks can reveal this difference. APTA rehabilitation guideline

Compare costs over the same period

The initial price of oral medicines, ongoing infusion consumables, DBS implantation and programming, and follow-up after ablation represent different cost structures. For Chinese hospital estimates, choose a common observation period and identify drugs, equipment, procedures, admission, review, and rehabilitation in renminbi. Specify exclusions. Two total prices with different durations and services are not directly comparable.

Travel, caregiving, and time near a treatment center also affect the family budget and are not necessarily included in the hospital estimate. Discuss rechargeable-device management, replacement pathways for nonrechargeable systems, lawful medication supply, and continuing consumables before selecting treatment. Without a current written quotation matched to a clinical plan, a numerical personal budget for China would not be reliable.

Make a shared decision that leaves a workable follow-up plan

Bring the two or three symptoms most worth improving, treatments already tried, adverse effects that would be unacceptable, and the support the household can realistically provide. Ask the team to explain its preferred pathway, reasonable alternatives, and what happens if benefit is insufficient. When specialists differ, the disagreement may concern the target or the risk assessment. Request the reasoning rather than being left to vote between procedure names.

The 2026 Chinese guideline describes continuing multidisciplinary management. For an international patient, this requires a plan connecting neurology, the procedural team, rehabilitation, and the clinician taking over at home. The aim is a patient-valued improvement with an acceptable burden and someone responsible for checking whether it is maintained. Completing a technology-based intervention is one step within that plan. Chinese fifth-edition guideline

Evidence verified: September 9, 2026. Individual indications, local device registration, and availability require confirmation by the receiving institution.